



ADULT Medication Monograph

LIDOCAINE (LIGNOCAINE)

This document should be read in conjunction with this [DISCLAIMER](#)

5% Patch (Versatis®/Nervoderm®): [Formulary: Restricted](#)

Others: [Formulary: Unrestricted](#)

 [HIGH RISK Medication](#)

Class	Local anaesthetic and antiarrhythmic	
Presentation	Lidocaine Products	
	Form	Strength
	Ampoule	200mg/20mL (1%)
	Ampoule	50mg/5mL (1%)
	Ampoule	100mg/5mL (2%)
	Ampoule	500mg/5mL (10%)
	Gel (Sterile Catheter Syringe)	20mg/mL (2%)
	Jelly	20mg/g (2%)
	Ointment	50mg/g (5%)
	Patch (Versatis®)	5%
	Special Adhesive Ointment	100mg/g (10%)
	Spray	100mg/mL (10%)
	Topical Solution SAS	40mg/mL (4%)
	Viscous Liquid (Xylocaine Viscous®)	20mg/mL (2%)
	Combination Products	
	Form	Active Ingredients and Strength
	Ampoule	Lidocaine 1% with Adrenaline 1:100,000
	Cartridge (Lignospan Special®)	Lidocaine 2% with Adrenaline 1:80,000
	Cream (Emla®)	Lidocaine 2.5% with Prilocaine 2.5% (5g, 30g)
	Infusion Bag (SAS)	Lidocaine in Glucose 5% 2g/500mL (0.4%)
Nasal Spray	Lidocaine 5% with Phenylephrine 0.5%	
Patch (Emla®)	Lidocaine 2.5% with Prilocaine 2.5%	
Vial	Lidocaine 2% with Adrenaline 1:200,000	

Storage	Store at room temperature, below 25°C 5% Patch (Versatis®): Use opened sachets within 14 days
Dose	Refer to KEMH Clinical Guidelines for appropriate dose regimes (links below) <u>Neuropathic Pain (5% Patch):</u> <i>For use only under the direction of a Pain Consultant, Palliative Care Physician or Geriatrician as per the WATAG guidelines for the treatment of neuropathic pain.</i> Transdermal: Up to 3 patches may be applied at the same time to painful area. Patch may be worn for up to 12 hours, followed by a patch-free interval of at least 12 hours. For post herpetic neuralgia, apply after shingles have healed.
Administration	Refer to KEMH Clinical Guidelines for appropriate dose regimes (links below) <u>Transdermal</u> Remove patch from pack and remove gel liner then immediately apply patch to dry, intact, non-irritated skin in the painful area (patches may be cut to fit the area). While wearing the patches, do not allow them to come in contact with water or any heat source (e.g. heat packs, electric blankets)
Pregnancy	1st Trimester: Safe to use 2nd Trimester: Safe to use 3rd Trimester: Safe to use
Breastfeeding	Safe to use
Monitoring	IV: Continuous ECG monitoring, blood pressure, oxygen saturation, sedation 5% Patch: Pain score and skin irritation. Stop if no benefits after 2 – 4 weeks.
Clinical Guidelines and Policies	KEMH Clinical Guidelines: Lidocaine (Lignocaine) Infusion: Intravenous Episiotomy and Infiltration of the Perineum Episiotomy/Genital Laceration: Suturing Operative Birth (previously known as Instrumental Vaginal Delivery) Structured Administration & Supply Arrangement (SASA):

	SASA Lidocaine (Lignocaine)
References	<p>The Royal Women's Hospital. Lidocaine. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2018 [cited 2020 Apr 16]. https://thewomenspbmg.org.au/</p> <p>Australian Medicines Handbook. Lidocaine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Apr 16]. Available from: https://amhonline.amh.net.au/</p> <p>Society of Hospital Pharmacists of Australia. Lidocaine. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2020 [cited 2020 Apr 16]. Available from: http://aidh.hcn.com.au</p> <p>MIMS Australia. Versatis 5% Patch. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2018 [cited 2020 May 21]. Available from: https://www.mimsonline.com.au</p> <p>Formulary One. Versatis 5% Patch, 2020 [cited 20 May 21]. Available from: https://formulary.health.wa.gov.au/Drug/724</p>

Keywords:	Lidocaine, Lignocaine, Pain, Xylocaine, Emla, Local anaesthetic, neuropathic pain, post herpetic neuralgia, Versatis, Nervoderma		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Chief Pharmacist		
Author / Reviewer:	Pharmacy Department		
Date first issued:	August 2015	Version:	4.0
Last reviewed:	June 2020	Next review date:	June 2023
Endorsed by:	Medicines and Therapeutics Committee	Date:	June 2020
Document history	Amalgamation of: <ul style="list-style-type: none"> • Lidocaine (Lignocaine) 2017 • Lidocaine (Lignocaine) 5% Patch 2018 		
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety, 8  Acute Deterioration		

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2020